Cg Oncology revenue was $4.04M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $2.3M, up 39.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CGON annual revenue was $4.0M, with 254.7% growth year-over-year.
CGON past revenue growth
How has CGON's revenue growth performed historically?
On Invalid Date, Cg Oncology (NASDAQ: CGON) reported Q4 2025 revenue of $2.32 million up 409.21% year over year. In the same quarter last year, Cg Oncology's revenue was $456.00 thousand.
What was Cg Oncology's revenue in 2025?
Cg Oncology's annual revenue for the twelve months ending Dec 31, 2025 was $4.04 million, a 254.7% increase year over year.
How much does Cg Oncology make in a day?
Based on Cg Oncology annual revenue for the past four years, CGON makes an average of $3,817.81 per day.
What was Cg Oncology's annual revenue growth in the past year?
As of Q1 2026, Cg Oncology's revenue has grown 254.7% year over year. This is 125.28 percentage points lower than the US Biotechnology industry revenue growth rate of 379.98%. Cg Oncology's revenue in the past year totaled $4.04 million.
How much does Cg Oncology make in a year?
Cg Oncology's revenue by year for the past four years is:
Cg Oncology's revenue for the twelve months ending Dec 31, 2025 was $4.04 million, a 254.7% increase year over year.
Cg Oncology's annual revenue for Dec 31, 2024 was $1.14 million, a 458.33% increase from 2023.
Cg Oncology's annual revenue for 2023 was $204.00 thousand, a 6.81% increase from 2022.
Cg Oncology's annual revenue for 2022 was $191.00 thousand, a 98.16% decrease from 2021.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.